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Abstract 
A stability-indicating reversed-phase high-performance liquid chromatographic 
(RP-HPLC) method was developed for the determination of sodium bisulfate 
(SB), an antioxidant, in injectable dosage form. The chromatographic separation 
was achieved on a Zorbax CN (250 mm × 4.6 mm, 5 µm) column, with a mobile 
phase consisting of a buffer mixture of 0.03 M tetrabutylammonium hydrogen 
sulfate, 0.01 M potassium dihydrogen orthophosphate, and acetonitrile at a ratio 
of 70:30 (v/v)  and  a flow rate of 0.7 mL/min. The eluted compound was 
monitored at a wavelength of 215 nm using a UV detector. The method 
described herein separated sodium bisulfite from all other formulation 
components within a run time of 10 min. The method also generated linear 
results over an SB concentration range of 10 to 990 µg/mL, and the limit of 
quantification was found to be 10 μg/mL. The stability indicating capability of the 
method was established by performing forced degradation experiments. The 
RP-HPLC method that was developed  was validated according to the 
International Conference on Harmonization (ICH) guidelines. This method was 
successfully applied in the quantitative determination of SB in a stability study of 
Amikacin sulfate injection. The procedure described herein is simple, selective, 
and reliable for routine quality control analysis as well as stability testing.  
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Introduction 
Sodium bisulfite (SB) is an inorganic compound commonly used as an antioxidant in 
pharmaceutical formulations.  Antioxidants are excipients that are used to improve the 
stability of medicines by delaying the oxidation of active substances and other excipients 
and are classified into 3 groups [1]. The first group is known as true antioxidants, or anti-
oxygen, which likely inhibit oxidation by reacting with free radicals  and  blocking chain 
reactions. The second group consists of reducing agents; these substances have lower 
redox potentials than the drug or adjuvant that they are intended to protect and are 
therefore more readily oxidized. Reducing agents may also operate by reacting with free 
radicals. The third group consists of antioxidant synergists that usually have little 
antioxidant effect themselves but are thought to enhance the action of antioxidants in the 
first group by reacting with heavy metal ions that catalyze oxidation. The chemical 
structure of SB is presented in Figure 1. 
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Fig. 1.  Chemical structure of sodium bisulfite 
SB is a common reducing agent that is used in both chemical and pharmaceutical 
industries. It readily reacts with dissolved oxygen and is converted into sodium hydrogen 
sulfate [2]. 
2 NaHSO3 + O2 → 2 NaHSO4 
SB is oftentimes added to large piping systems to prevent oxidative corrosion. In 
biochemical engineering applications, SB is helpful in maintaining anaerobic conditions 
within a reactor. The antioxidant properties are due to certain chemical groups which are 
usually harmful to living cells and might therefore be associated with certain risks when 
used in humans [3]. Thus, inclusion of antioxidants in any finished products needs special 
justification. Finished product release specifications should include an identification test 
and a content determination test with acceptance criteria and limits for each antioxidant 
present in a formulation. The finished product’s shelf-life specification should also include 
an identification test and limits for any antioxidants present [3]. Whenever antioxidants are 
expended during the manufacturing of a product, the release limits should be justified by 
batch data. The adequacy of specified limits should be justified on the basis of controlled 
conditions and in-use stability testing to ensure that sufficient antioxidant remains to 
protect the product throughout its entire shelf-life and during the proposed in-use period 
[3]. The antioxidant properties of SB are therefore an integral part of product formulation. 
This concept encourages the development of new a stability-indicating method for the 
estimation of SB in today’s chemical and pharmaceutical industries.   A Stability Indicating Method for the Determination of the Antioxidant Sodium Bisulfite in …  911 
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A detailed literature survey for SB revealed that a spectroscopic method is available for the 
determination of sulfite content in aqueous medium using Ellman’s reagent [4]. Another 
method allows for the determination of sodium metabisulfite in parenteral formulations by 
high performance ion chromatography [5]. In this technique, the correlation coefficient was 
found to be less (>0.99), the sample precision value was higher than 6.0 % and the 
stability-indicating capability of the method was not demonstrated according to  ICH 
guidelines [6]. Moreover, SB is not officially represented in any pharmacopoeia to date. 
There is no stability-indicating HPLC method reported in the literature that can adequately 
separate and accurately quantify SB in Amikacin injection, thus necessitating the 
development of a new stability-indicating method to assay SB in pharmaceutical 
formulation.  
The purpose of this study was to develop a stability-indicating method for the 
determination of SB in injection formulation. The method developed was able to separate 
SB from Amikacin sulfate and other excipients of a drug product within 10 min.  Upon 
successful separation, this technique was validated as per ICH guidelines [6] and 
successfully applied in the separation and quantification of SB in Amikacin sulfate 
injections.  
Results and Discussion 
Method development and optimization 
The main criterion for developing an RP-HPLC method for the determination of SB as an 
inorganic compound using a UV detector was to estimate the amount of SB in a single run, 
with emphasis on the method being accurate, reproducible, robust, stability indicating, 
linear, free of interference from other formulation excipients and convenient enough for 
routine use in quality control laboratories.  
Tab. 1.   Label claim of SB with its working concentration (specification limit) 
Compound  Label claim mg/mL  Working concentration 
(mg/mL)  (µg/mL) 
SB  6.6 mg  0.66  660 
 
A spiked solution of SB (660 µg/mL) and placebo peaks were subjected to separation by 
RP-HPLC. Initially, the separation of all peaks was studied using water as mobile phase A 
and acetonitrile as mobile phase B on an HPLC column (Hypersil BDS-C18) and Waters 
(HPLC) system with a linear gradient program. The 0.5 mL/min flow rate was selected to 
achieve the separation of peaks. The column oven temperature was maintained at 25°C. 
These conditions resulted in merging of the SB peak with the placebo peaks, represented 
in Figure 3. Based on this result, the C18 column was replaced with a polar cyano column 
in an effort to achieve high resolution between the placebo peak and the SB peak. With 
the cyano column (Zorbax CN), different combinations of mobile phase A and B were 
studied to optimize the method, and the results of the optimization are summarized in 
Table 2, including any observations noted. From the mobile phase selection study, the 
optimized HPLC parameters were as follows: flow rate, 0.7 mL/min; column oven 
temperature, 30°C; injection volume, 10 µL; and an isocratic program with a mixture of 912  H. K. Trivedi and M. C. Patel:   
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buffers (0.03 M tetrabutylammonium hydrogen sulfate (TBAS) and 0.01 M potassium 
dihydrogen orthophosphate in Milli-Q water adjusted to pH 6.0 with orthophosphoric acid) 
and acetonitrile in the ratio of 70:30 (v/v) as the mobile phase. The column oven 
temperature was also studied; it was found that 30°C was a more appropriate temperature 
with respect to peak separation and shape. Based on the UV spectrum of the compound, 
215 nm was found to be appropriate for the determination of SB in pharmaceutical 
formulations. SB and other excipients are well resolved with respect to each other in a 
reasonable time of 10 minutes (Figure 2). No chromatographic interference due to the 
blank (diluent) and other excipients (placebo) at the retention time of SB was observed, as 
shown in Figure 2. 
 
Fig. 2.  Overlaid chromatograms of placebo, blank and standard (SB) 
 
Fig. 3.  Overlaid chromatograms (unsuccessful conditions) of standard (SB) and 
sample solution.  
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Tab. 2.  Summary of method optimization  
Experimental condition  Observation 
Water(MP-A) and acetonitrile (MP-B), linear gradient; 
Hypersil BDS-C18 (250 mm × 4.6 mm, 5 µm); 25°C  
SB peak was merged 
with placebo peak 
0.01 M KH2PO4 (MP-A) and acetonitrile (MP-B), 
linear gradient; Hypersil BDS-C18 
(250 mm × 4.6 mm, 5 µm); 25°C  
SB peak was merged 
with placebo peak 
0.01 M KH2PO4 + 0.03 M TBAS (MP-A) and 
acetonitrile (MP-B), linear gradient; Hypersil BDS-
C18 (250 mm × 4.6 mm, 5 µm); 25°C  
Slight peak separation 
was observed 
0.01 M KH2PO4 + 0.03 M TBAS (MP-A) and 
acetonitrile (MP-B), linear gradient; Zorbax CN 
(250 mm × 4.6 mm, 5 µm); 25°C  
SB peak was 
separated from 
placebo 
0.01 M KH2PO4 + 0.03 M TBAS, pH 6.0 with H3PO4 
(buffer) and acetonitrile, (70:30) v/v; Zorbax CN 
(250 mm × 4.6 mm, 5 µm); 30°C  
Satisfactory peak 
separation and peak 
shape 
 
Analytical parameters and validation 
After development, this method was subjected to validation according to ICH guidelines 
[6]. The method was validated to demonstrate that it is suitable for its intended purpose by 
the standard procedure to evaluate adequate validation characteristics (system suitability, 
accuracy, precision, linearity, robustness, solution stability and stability-indicating 
capability).  
Tab. 3.  System suitability results (precision, intermediate precision and robustness) 
Parameter  Theoretical 
plates* 
Tailing 
factor* 
% RSD* of 
standard 
Precision  2950  1.1  1.00 
Intermediate Precision  3222  1.0  0.72 
At 0.6 mL/min flow rate  2604  1.2  0.54 
At 0.8 mL/min flow rate  2734  1.1  0.82 
At 25°C column temp.  2678  1.1  0.67 
At 35°C column temp.  2879  1.0  0.78 
At buffer pH 5.9  2750  1.1  1.10 
At buffer pH 6.1  2938  1.1  0.71 
At 213 nm  2812  1.2  0.53 
At 217 nm  2910  1.2  0.58 
* Determined on six values. 
 
System suitability 
The percentage relative standard deviation (RSD) of area from six replicate injections was 
below 2.0 %. Low values of RSD for replicate injections indicate that the system is precise. 
The results of other system suitability parameters such as peak tailing and theoretical 914  H. K. Trivedi and M. C. Patel:   
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plates are presented in Table 3. As seen from this data, the acceptable system suitability 
parameters would be as follows: the relative standard deviation of replicate injections is 
not more than 2.0 %, the tailing factor for the peak of SB is not more than 1.5 and the 
theoretical plates are not less than 2000.  
Specificity 
Forced degradation studies were performed to demonstrate the selectivity and stability-
indicating capability of the proposed RP-HPLC method. Figure 2 shows that there is no 
interference at the RT (retention time) of SB from the blank and other excipients. 
Significant degradation was not observed when SB was subjected to acid, base, thermal, 
hydrolytic and UV conditions, whereas significant degradation was observed when the SB 
was subjected to oxidative hydrolysis (3% H2O2, 60°C, 30 minutes), leading to the 
formation of sodium hydrogen sulfate. The oxidative product (sodium hydrogen sulfate) 
and SB are well separated from each other, as seen in Figure 4. The peak attributed to SB 
was investigated for spectral purity in the chromatogram of all exposed samples and was 
found to be spectrally pure. The purity and assay of SB was unaffected by the presence of 
other excipients and thus confirms the stability-indicating power of this method. The results 
of the forced degradation study are presented in Table 4.  
Tab. 4.  Summary of forced degradation results  
Degradation condition  Assay  
(% w/w) 
Purity  
Flag  Observation 
Control sample  99.8  No  Not applicable 
Acid hydrolysis (0.5 N HCl, 60°C, 1 h)  98.5  No  SB found stable 
Alkaline hydrolysis (0.5 N NaOH, 60°C, 1 h)  98.4  No  SB found stable 
Oxidation (3 % H2O2, 60°C, 30 min)  78.3  No  SB found sensitive 
Thermal (60 °C, 6 h)   100.8  No  SB found stable 
Exposed to UV at 254 nm  100.1  No  SB found stable 
 
 
Fig. 4.  Overlaid chromatograms of SB and sodium hydrogen sulfate 
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Limit of quantification (LOQ) 
The concentration (in μg/mL) with a signal to noise ratio (S/N) of at least 10 was taken as 
the LOQ, which meets the criteria defined by ICH guidelines. The LOQ for the SB peak 
was found to be 10 μg/mL. The precision was also established at the quantification level. 
The % RSD of the  peak area was well within the acceptance limit of <10.0 %. The 
determined limit of qualification and precision at LOQ values for SB is presented in 
Table 5.  
Tab. 5.  LOQ and its precision results 
Substance  LOQ (µg/mL)  S/N  Precision (% RSD*) 
SB  10  10.2  2.3 % 
* Determined on six values 
 
Linearity 
The linearity of an analytical method is its ability to elicit test results that are directly, or by 
a well-defined mathematical transformation, proportional to the concentration of analyte in 
that sample within a given range. The response was found to be linear from 1.5 % to 
150 % of standard concentration. The regression statistics are shown in Table 6, with the 
linearity curve for SB represented in Figure 5. 
Tab. 6.  Regression statistics 
Subst.  Linearity 
range (µg/mL) 
Correlation 
Coefficient 
(R
2) 
Linearity  
(Equation) 
Y-intercept  
bias in % 
p-value* 
SB  10 to 990  0.999  y = 4784.091X – 
21862.705 
0.7  0.0001 
* Calculated by Statistical Analytical Software, Version 9.2  
 
 
Fig. 5.  Linearity of SB 916  H. K. Trivedi and M. C. Patel:   
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Precision 
The purpose of this study was to demonstrate the reliability of the test results with 
variations. The average % assay (n = 6) of SB was 99.8 % with RSD of 1.0 %. The results 
are shown in Table 7, along with intermediate precision data. Low RSD values indicate 
that this method is precise.  
Tab. 7.  Precision (660 µg/mL) and Intermediate precision (660 µg/mL) results 
Substance  Precision   Intermediate precision 
% Assay 
#  % RSD*  % Assay 
#  % RSD* 
SB  99.8  1.0  101.0  0.7 
# Average of six determinations; * Determined on six values. 
 
Accuracy 
The accuracy of an analytical method is the closeness of test results obtained by that 
method compared with the true values. The amount recovered (for 10, 50, 100 and 150 % 
level) was within ± 2 % of amount added; for the LOQ level, the amount recovered was 
within ± 10 % of the amount added, indicating that the method is accurate and that there is 
no interference due to other excipients present in the injection. The results of the recovery 
assay are shown in Table 8.  
Tab. 8.  Accuracy results of SB 
  At LOQ 
10 µg/mL 
At 10 % 
66 µg/mL 
At 50 % 
330 µg/mL 
At 100 % 
660 µg/mL 
At 150 % 
990 µg/mL 
% Recovery
#  103.6  101.6  99.7  98.5  98.6 
% RSD*  3.0  0.44  0.91  0.85  0.60 
* Determined on three values; 
# Mean of three determinations. 
 
Robustness 
The robustness of an analytical procedure is a measure of its capacity to remain 
unaffected by small but deliberate variations in method parameters and provides an 
indication of its reliability during normal usage.  No significant effect was observed on 
system suitability parameters such as RSD, tailing factor, or the theoretical plates of SB 
when small but deliberate changes were made to chromatographic conditions. The results 
are presented in Table 3, along with the system suitability parameters of normal 
conditions. Thus, the method was found to be robust with respect to variability in applied 
conditions. 
Stability of the sample solution 
Drug stability in pharmaceutical formulations is a function of storage conditions and 
chemical properties of the SB. Conditions used in stability experiments should reflect 
situations likely to be encountered during actual sample handling and analysis. Stability 
data are required to show that the concentration and purity of analyte in the sample at the   A Stability Indicating Method for the Determination of the Antioxidant Sodium Bisulfite in …  917 
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time of analysis corresponds to the concentration and purity of analyte at the time of 
sampling. A sample solution did not show any appreciable change in assay value when 
stored at ambient temperature up to 24 h (Table 9). The results from solution stability 
experiments confirmed that the sample solution was stable for up to 24 h during the assay 
procedure.  
Tab. 9.  Solution stability results 
% Assay   Initial  After 24 hrs. 
101.2  100.9 
 
Application of the method to stability study 
The present method was applied for the estimation of SB during a stability study. The 
results obtained are presented in Table 10.  
Tab. 10.  Results of stability study (Amikacin injection)  
Sample ID  % Assay of SB 
Initial  99.8 % 
1 M 40 °C /75 % RH  85.3 % 
2 M 40 °C /75 % RH  77.2 % 
3 M 40 °C /75 % RH  62.5 % 
6 M 40 °C /75 % RH  46.3 % 
 
Experimental 
Materials and Reagents  
Amikacin sulfate injection and placebo solution were provided by Cadila Pharmaceutical 
Ltd. Dholka, Ahmedabad, India, along with the working standard. HPLC grade acetonitrile 
and methanol were obtained from J.T. Baker (NJ., USA). GR grade potassium dihydrogen 
phosphate, tetrabutylammonium hydrogen sulfate and orthophosphoric acid were obtained 
from Merck Ltd. (Mumbai, India). Nylon membrane filters (0.22 µm) and nylon syringe 
filters were purchased from Pall Life Science Limited (India). High purity water was 
generated with Milli-Q Plus water purification system (Millipore, Milford, MA, USA).  
Buffer preparation 
A solution of 0.01 M phosphate buffer (KH2PO4) and 0.03 M tetrabutylammonium 
hydrogen sulfate was prepared using Milli-Q water. The pH was adjusted to 6.0 with 
orthophosphoric acid. The buffer preparation was stable with respect to pH and maintained 
visual clarity for 48 h.  
Chromatographic conditions 
Analysis was performed on an Alliance Waters HPLC system consisting of a quaternary 
solvent manager, sample manager, and PDA (photo diode array) detector. System control, 918  H. K. Trivedi and M. C. Patel:   
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data collection, and data processing were accomplished using Waters Empower 
chromatography data software. The chromatographic conditions were optimized on  an 
Agilent Zorbax CN (250 mm x 4.6 mm, 5 µm) column. The mobile phase was a mixture of 
buffer and acetonitrile at a ratio of 70:30 (v/v). The mobile phase was filtered through 
0.22 µm nylon membrane filter and degassed under vacuum prior to use. Purified water 
was used as a diluent. The optimized conditions were as follows: an injection volume of 
10 µL, isocratic elution at a flow rate of 0.7 mL/min, 30°C (column oven) temperature, and 
215 nm detection wavelength. Under these conditions, the backpressure in the system 
was approximately 2,000 psi. The stress degraded samples were analyzed using a PDA 
detector over a range of 200–400 nm.  
Standard solution preparation  
The standard solution was prepared by dissolving the standard in diluent to obtain a 
solution containing 660 µg/mL of SB.  
Sample solution preparation 
For the preparation, 2.0 mL of sample solution was accurately transferred into a 20 mL 
volumetric flask. Approximately 15 mL of diluent was added to the volumetric flask, which 
was then sonicated in an ultrasonic bath for 3 min. The resulting solution was then diluted 
up to the mark with diluent and mixed well.  
Placebo solution preparation 
In preparing the placebo solution, 2.0 mL of placebo solution was accurately transferred 
into a 20 mL volumetric flask. Approximately 15 mL of diluent was added to the volumetric 
flask, which was then sonicated in an ultrasonic bath for 3 min. The resulting solution was 
then diluted up to the mark with diluent and mixed well.  
Method validation 
The method described herein has been validated for assay determination by HPLC. 
System suitability 
System suitability parameters were performed to verify the system performance. System 
precision was determined on six replicate injections of standard preparations. All  the 
important characteristics,  including the relative standard deviation, peak tailing, and 
theoretical plate number, were measured. 
Specificity 
Forced degradation studies were performed to demonstrate selectivity and stability-
indicating the capability of the proposed method. The sample was exposed to acidic (0.5 N 
HCl, 60 °C, 1 h), alkaline (0.5 N NaOH, 60 °C, 1 h), strong oxidizing (3 % H2O2, 60 °C, 30 
min), thermal (60 °C, 6 h) and photolytic (UV) degradation conditions. All exposed samples 
and standards were then analyzed by the proposed method. 
Limit of quantification (LOQ) 
The LOQ was determined using a signal to noise approach as defined in the International 
Conference on Harmonization (ICH) guidelines [6]. A serially diluted solution of SB was   A Stability Indicating Method for the Determination of the Antioxidant Sodium Bisulfite in …  919 
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injected into the chromatograph and the signal to noise (S/N) ratio was calculated at each 
concentration.  
Linearity 
Linearity was demonstrated from 1.5 to 150 % of standard concentration using a minimum 
of seven calibration levels (1.5 %, 10 %, 50 %, 75 %, 100 %, 125 % and 150 %) for SB. 
The method of linear regression was used for data evaluation. The peak area of the 
standard compound was plotted against the respective SB concentrations. Linearity was 
described by the linearity equation and the correlation coefficient was also determined. 
Precision  
The precision of the system was determined using the sample preparation procedure 
described above for six real samples of Amikacin sulfate injection and analysis using the 
same proposed method. Intermediate precision was studied using different columns and 
was performed on different days. 
Accuracy 
To confirm the accuracy of the proposed method, recovery experiments were carried out 
by the standard addition technique. Five levels (LOQ, 10 %, 50 %, 100 % and 150 %) of 
standards were added to pre-analyzed samples in triplicate. The percentage recoveries of 
SB at each level and each replicate were determined. The mean of percentage recoveries 
(n = 15) and the relative standard deviation were also calculated. 
Robustness 
The robustness is a measure of the capacity of a method to remain unaffected by small 
but deliberate changes in flow rate (± 0.1 mL/min), change in column oven temperature 
(± 5 °C), change in pH of buffer (± 0.1) and change in wavelength nm (± 2 nm).  
Stability of sample preparation 
The stability of the sample solution was established by storage of the sample solution at 
ambient temperature for 24 h. The sample solution was re-analyzed after 24 h, and the 
results of the analysis were compared with the results of the fresh sample. 
Conclusion 
A new RP-HPLC method was successfully developed for the estimation of sodium bisulfite 
in Amikacin Injection. The method validation results have verified that the method is 
selective, precise, accurate, linear, robust and stability indicating. The run time (10.0 min) 
enables rapid determination of SB. This stability-indicating method can be applied for the 
determination of sodium bisulfite in release testing and  in  stability studies  of Amikacin 
Injection. Moreover, it may be applied for the determination of SB in bulk drugs, chemical 
processing  or in reverse engineering techniques to identify reacted and un-reacted 
quantities of SB. 
 920  H. K. Trivedi and M. C. Patel:   
Sci Pharm. 2011; 79: 909–920 
Acknowledgement 
The authors would like to thank M/s Cadila Pharmaceutical Ltd. for supporting this work. 
All the development and validation work performed at  Analytical Research and 
Development Lab., Cadila Pharmaceutical Ltd., Ahmedabad, India. 
Authors’ Statement 
Competing Interests 
The authors declare no conflict of interest.  
References 
[1]  Fahelelbom KMS, El-Shabrawy Y. 
Analysis of preservative in pharmaceutical products. 
Pharm Rev. 2007; 5(1). 
[2]  Troy DB (ed). 
Remington: The Science and Practice of Pharmacy. 
Lippincott Williams & Wilkins, Philadelphia, 21st ed., 2006. 
[3]  European Medicines Agency.  
Guideline on Excipients in the Dossier for Application for Marketing Authorisation of a Medicinal 
Product. 
Doc. Ref. EMEA/CHMP/QWP/396951/2006; London, 6 November 2006. 
[4]  Sadegh C, Schreck RP. 
Academy for the advancement of science and technology, Hackensack NJ. 
The spectroscopic determination of aqueous sulfite using Ellman’s reagent. 
MIT Undergrad Res J. 2003; 8: 39–43.  
[5]  Herbranson DE, Eliason MS, Karnatz NN. 
Development of a high performance ion chromatographic (HPIC) method for the determination of 
sodium metabisulfite in parenteral formulations.  
J Liq Chromatogr. 1987; 10: 3441–3450. 
http://dx.doi.org/10.1080/014839187080818820 
[6]  International conference on Harmonization: 
ICH, Validation of Analytical Procedure, Text and Methodology Q2(R1). 
IFPMA, Geneve, Switzerland, 2005. 